Skip to search formSkip to main contentSkip to account menu

EMD 121974

Known as: EMD-121974, EMD121974 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

CilengitideCyclic Peptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Differential growth inhibition of cerebral metastases by anti-angiogenic compounds.
BACKGROUND The formation of brain metastases is intrinsically linked to concomitant angiogenesis. The purpose of the present… 
2011
2011
L’inhibiteur d’intégrines Cilengitide : un nouveau principe actif en neuro-oncologie
Resume Ces dernieres annees ont vu l’essor des strategies antiangiogeniques dans le traitement des cancers. Parmi elles, le… 
Review
2011
Review
2011
[The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
Last years saw the development of anti-angiogenic strategies in the treatment of cancers. Cilengitide (EMD121974; Merck KGaA… 
2009
2009
In vivo molecular changes in patients (pts) with metastatic melanoma treated with EMD121974 (selective antagonist of avβ3 integrin).
9058 Background: αvβ3 integrin promotes the proliferation of tumor-associated endothelial ells and potentiates the survival of… 
Review
2008
Review
2008
Current available therapies and future directions in the treatment of malignant gliomas
The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing… 
2006
2006
A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic αvβ3 and αvβ5 integrin antagonist, in patients with advanced solid malignancy.
3052 Background: Integrins αvβ3 and αvβ5 are cell-surface receptors that play a significant role in angiogenesis by mediating the… 
2006
2006
A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic {alpha}v{beta}3 and {alpha}v{beta}5 integrin antagonist, in patients with advanced solid malignancy
2005
2005
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
Eleven gamma-aminocyclopentane carboxylic acid (Acpca) platforms, including four dihydroxy representatives (19-22), three hydroxy… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)